drugset / Trial / NCT06218199
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
RandomizedParallel-groupOpen-labelTreatment
Summary
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Timeline
- Start
- 2021-07-08
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bumetanide | Small molecule | 1 mg | Oral |
| Comparator | Furosemide | Other / unclassified | 40 mg | Oral |
| Comparator | Furosemide | Other / unclassified | 480 mg | Oral |
| Comparator | Hydralazine | Small molecule | 10 mg | Oral |
| Comparator | Isosorbide Dinitrate | Other / unclassified | 10 mg | Oral |
| Comparator | Torsemide | Other / unclassified | 20 mg | Oral |
| Comparator | sacubitril/valsartan | Unknown | 24 mg | Oral |
| Comparator | sacubitril/valsartan | Unknown | 49 mg | Oral |